Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Paclitaxel 11Fluorouracil 10pembrolizumab 9Cisplatin 9Radiotherapy 7Carboplatin 6Esophagectomy 5Nivolumab 4Drug Therapy 4Radiotherapy, Intensity-Modulated 3Leucovorin 3Chemoradiotherapy 3Cetuximab 3Capecitabine 3durvalumab 2atezolizumab 2Oxaliplatin 2Ipilimumab 2spartalizumab 1sintilimab 1selinexor 1regorafenib 1prexasertib 1osimertinib 1niraparib 1nilotinib 1nedaplatin 1nanocis 1fludarabine 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × nanocis × Gastrointestinal × Clear all
NCT02997553 2023-01-09

GASVERT

Institut de Cancérologie de Lorraine

Phase 3 Completed
744 enrolled
BreastDermatologicGastrointestinalGynecologicHead & Neck

Anus Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡